ArticleClinical, cosmetic and investigational dermatology2022
Identification of Serum Biomarkers and Pathways of Systemic Lupus Erythematosus with Skin Involvement Through GC/MS-Based Metabolomics Analysis.
Article in Clinical, cosmetic and investigational dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
- An Overview of the Pathogenesis of Cutaneous Lupus Erythematosus.Journal of clinical medicine · 2025Review
- Metabolic profiling of urinary exosomes for systemic lupus erythematosus discrimination based on HPL-SEC/MALDI-TOF MS.Analytical and bioanalytical chemistry · 2023Article
- Metabolomic and Proteomic Identification of Serum Exosome for Hypoxic Preconditioning Participants.Oxidative medicine and cellular longevity · 2023Article
- Advanced methods and novel biomarkers in autoimmune diseases ‑ a review of the recent years progress in systemic lupus erythematosus.Frontiers in medicine · 2023Review
- Serum Metabolomics Analysis of Skin-Involved Systemic Lupus Erythematosus: Association of Anti-SSA Antibodies with Photosensitivity.Journal of inflammation research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSkin involvement is the second most common symptom of systemic lupus erythematosus (SLE), and the prevention of skin lesion development might benefit to lessen the system inflammation burden in SLE. However, the mechanisms of skin lesion in SLE remain unclear. PATIENTS AND
methodsMetabolome based on gas chromatography-mass spectrometry (GC-MS) was used for comparison of serum metabolism among 11 SLE patients with skin lesion (SL), 10 SLE patients without skin lesion (SNL), and 16 healthy controls (HC). The analysis of metabolism profiles was through LUG database, Human Metabolome Database (HMDB) as well as Kyoto Encyclopedia of Genes and Genomes (KEGG).
resultsA total of 14 most meaningful metabolites were found in SL patients compared to SNL patients, and 19 metabolic pathways were enriched. Meanwhile, L-alpha-aminobutyric acid, dehydroascorbic acid, glycine, and L-tyrosine achieved an area under receiver-operating characteristic (ROC) curve of 0.8636, 0.8091, 0.7727, and 0.7636, respectively, indicating their diagnostic potential for SL patients. In addition, the combined model of L-alpha-aminobutyric acid and dehydroascorbic acid provided better diagnostic accuracy.
conclusionThe metabolomic features of SLE patients with skin lesion could be detected by GC/MS assay. Our study tried to provide new insights into the mechanism of SLE skin injury. Further validation of these findings through larger sample size studies may contribute to the use of metabolic profile analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.